UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

Diabetologia, 2013-12, Vol.56 (12), p.2582-2592

2013

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.467-477

2014

Volltextzugriff (PDF)

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.294-303

2015

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Diabetes, obesity & metabolism, 2013-04, Vol.15 (4), p.372-382

2013

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Diabetes, obesity & metabolism, 2013-05, Vol.15 (5), p.463-473

2013

Volltextzugriff (PDF)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.426-429

2015

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

International journal of clinical practice (Esher), 2013-12, Vol.67 (12), p.1267-1282

2013

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.1016-1027

2014

Volltextzugriff (PDF)

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.23-31

2015

Volltextzugriff (PDF)

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2016-01, Vol.18 (1), p.82-91

2016

Volltextzugriff (PDF)

Regulation of Tissue Injury Responses by the Exposure of Matricryptic Sites within Extracellular Matrix Molecules

The American journal of pathology, 2000-05, Vol.156 (5), p.1489-1498

2000

Volltextzugriff (PDF)

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Diabetes, obesity & metabolism, 2007-03, Vol.9 (2), p.194-205

2007

Volltextzugriff (PDF)

Glycaemic efficacy of canagliflozin is largely independent of baseline [beta]-cell function or insulin sensitivity

Diabetic medicine, 2016-12, Vol.33 (12), p.1744

2016

Volltextzugriff (PDF)

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity

Diabetic medicine, 2016-12, Vol.33 (12), p.1744-1747

2016

Volltextzugriff (PDF)

Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

Clinical medicine & research, 2009-06, Vol.7 (1-2), p.21-31

2009

Volltextzugriff (PDF)

A theoretical model for F-actin remodeling in vascular smooth muscle cells subjected to cyclic stretch

Journal of theoretical biology, 2007-05, Vol.246 (1), p.87-99

2007

Volltextzugriff (PDF)

Time-dependent Changes in Smooth Muscle Cell Stiffness and Focal Adhesion Area in Response to Cyclic Equibiaxial Stretch

Annals of biomedical engineering, 2008-03, Vol.36 (3), p.369-380

2008

Volltextzugriff (PDF)

PO417 CANAGLIFLOZIN ADDED ON TO ALPHA-GLUCOSIDASE INHIBITORS WITH OR WITHOUT OTHER ANTIHYPERGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Diabetes research and clinical practice, 2014-11, Vol.106, p.S258-S258

2014

Volltextzugriff (PDF)

Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

Value in health, 2014-05, Vol.17 (3), p.A239-A239

2014

Volltextzugriff (PDF)

PO422 EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM INDIA

Diabetes research and clinical practice, 2014-11, Vol.106, p.S260-S261

2014

Volltextzugriff (PDF)

P338 Comparaison entre la canagliflozine et la sitagliptine chez des sujets diabétiques de type 2 sous metformine et sulfamide hypoglycémiant

Diabetes & metabolism, 2014-03, Vol.40, p.A107-A107

2014

Volltextzugriff (PDF)

P321 Infection urinaire sous canagliflozine chez des sujets présentant un diabète de type 2

Diabetes & metabolism, 2014-03, Vol.40, p.A103-A103

2014

Volltextzugriff (PDF)

Cellular mechanisms involved in the vascular myogenic response

American journal of physiology. Heart and circulatory physiology, 1992-09, Vol.263 (3), p.H647-H659

1992

Volltextzugriff (PDF)

P304 Efficacité et tolérance de la canagliflozine sur une période de 52 semaines chez des patients diabétiques de type 2 présentant une insuffisance rénale chronique

Diabetes & metabolism, 2014-03, Vol.40, p.A99-A99

2014

Volltextzugriff (PDF)

Novel genomic targets in oxidant-induced vascular injury

Journal of molecular and cellular cardiology, 2005-06, Vol.38 (6), p.983-996

2005

Volltextzugriff (PDF)

1 – 25 von 413

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(365)
Mit Volltextzugriff
(345)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(243)
Life Sciences & Biomedicine
(231)
Humans
(166)
Male
(143)
Animals
(123)
Biological And Medical Sciences
(114)
Female
(95)
Middle Aged
(72)
Medical Sciences
(68)
Rats
(65)
Aged
(54)
Fundamental And Applied Biological Sciences. Psychology
(50)
Cardiovascular System & Cardiology
(48)
Neurosciences & Neurology
(48)
Adult
(44)
Physiology
(44)
Clinical Neurology
(41)
Cardiac & Cardiovascular Systems
(36)
Neurology
(33)
Amyotrophic Lateral Sclerosis - Genetics
(32)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

Regulation of Tissue Injury Responses by the Exposure of Matricryptic Sites within Extracellular Matrix Molecules

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Glycaemic efficacy of canagliflozin is largely independent of baseline [beta]-cell function or insulin sensitivity

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity

Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

A theoretical model for F-actin remodeling in vascular smooth muscle cells subjected to cyclic stretch

Time-dependent Changes in Smooth Muscle Cell Stiffness and Focal Adhesion Area in Response to Cyclic Equibiaxial Stretch

PO417 CANAGLIFLOZIN ADDED ON TO ALPHA-GLUCOSIDASE INHIBITORS WITH OR WITHOUT OTHER ANTIHYPERGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

PO422 EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM INDIA

P338 Comparaison entre la canagliflozine et la sitagliptine chez des sujets diabétiques de type 2 sous metformine et sulfamide hypoglycémiant

P321 Infection urinaire sous canagliflozine chez des sujets présentant un diabète de type 2

Cellular mechanisms involved in the vascular myogenic response

P304 Efficacité et tolérance de la canagliflozine sur une période de 52 semaines chez des patients diabétiques de type 2 présentant une insuffisance rénale chronique

Novel genomic targets in oxidant-induced vascular injury

Suchergebnisse filtern